Los Angeles Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Los Angeles Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$19.6M	Sell	149,111 -1,142,167	-88%	-$152M	0.08%	187
2025 Q4	$178M	Buy	1,291,278 +88,522	+7%	+$12.8M	0.61%	33
2025 Q3	$169M	Buy	1,202,756 +458,106	+62%	+$62.1M	0.57%	33
2025 Q2	$93.6M	Buy	744,650 +740,842	+19,455%	+$85M	0.35%	61
2025 Q1	$421K	Sell	3,808 -509,012	-99%	-$64.5M	﹤0.01%	793
2024 Q4	$70M	Buy	512,820 +92,072	+22%	+$11.4M	0.28%	74
2024 Q3	$48.5M	Buy	420,748 +363,863	+640%	+$49.9M	0.2%	104
2024 Q2	$7.83M	Sell	56,885 -188,496	-77%	-$25.8M	0.03%	288
2024 Q1	$33.8M	Sell	245,381 -673,010	-73%	-$91.9M	0.12%	160
2023 Q4	$121M	Buy	918,391 +364,986	+66%	+$42M	0.45%	52
2023 Q3	$62.3M	Buy	553,405 +2,807	+0.5%	+$296K	0.26%	78
2023 Q2	$51.9M	Sell	550,598 -84,247	-13%	-$8.23M	0.21%	98
2023 Q1	$64.3M	Sell	634,845 -128,847	-17%	-$13.4M	0.29%	82
2022 Q4	$91.2M	Sell	763,692 -28,274	-4%	-$3.31M	0.44%	56
2022 Q3	$84.1M	Buy	+791,966	New	+$80.4M	0.44%	51
2021 Q4	–	Sell	-14,016	Closed	-$1.34M	–	1449
2021 Q3	$1.34M	Sell	14,016 -5,177	-27%	-$489K	0.01%	651
2021 Q2	$1.87M	Sell	19,193 -36,255	-65%	-$3.48M	0.01%	601
2021 Q1	$5.39M	Sell	55,448 -90,189	-62%	-$9.46M	0.02%	397
2020 Q4	$14M	Sell	145,637 -31,120	-18%	-$3.01M	0.06%	227
2020 Q3	$17M	Buy	176,757 +43,631	+33%	+$5.05M	0.08%	186
2020 Q2	$16.2M	Buy	133,126 +122,431	+1,145%	+$13.5M	0.08%	205
2020 Q1	$926K	Buy	10,695 +2,395	+29%	+$234K	0.01%	732
2019 Q4	$892K	Buy	8,300 +4,730	+132%	+$495K	﹤0.01%	871
2019 Q3	$322K	Sell	3,570 -14,380	-80%	-$1.34M	﹤0.01%	1110
2019 Q2	$1.52M	Sell	17,950 -7,060	-28%	-$580K	0.01%	713
2019 Q1	$2.2M	Buy	25,010 +21,040	+530%	+$1.76M	0.01%	631
2018 Q4	$283K	Buy	3,970 +1,880	+90%	+$180K	﹤0.01%	1124
2018 Q3	$257K	Sell	2,090 -3,570	-63%	-$405K	﹤0.01%	1269
2018 Q2	$556K	Sell	5,660 -2,410	-30%	-$216K	﹤0.01%	1105
2018 Q1	$669K	Buy	+8,070	New	+$681K	﹤0.01%	945

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Los Angeles Capital Management's NBIX Position: Q1 2026 in Review

Los Angeles Capital Management reduced its Neurocrine Biosciences (NBIX) stake by 88% in Q1 2026, selling an estimated $152M and leaving 149,111 shares worth $19.6M. The position accounts for 0.08% of the portfolio, ranked #187.

Los Angeles Capital Management first reported a position in NBIX in Q1 2018 and has held it in 30 quarters since. The position peaked at $178M in Q4 2025. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Los Angeles Capital Management held 149,111 shares of Neurocrine Biosciences worth $19.6M as of Q1 2026.
Los Angeles Capital Management sold 1,142,167 Neurocrine Biosciences shares in Q1 2026, an estimated $152M.
Neurocrine Biosciences made up 0.08% of Los Angeles Capital Management's portfolio in Q1 2026, its #187 holding.
Los Angeles Capital Management first reported a position in Neurocrine Biosciences in Q1 2018 and has held it in 30 quarters since.
Los Angeles Capital Management's Neurocrine Biosciences position peaked at $178M in Q4 2025.
695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.